{"id":"oseltamivir-phosphate-granules","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"5","effect":"Abdominal pain"},{"rate":"2","effect":"Headache"},{"rate":"3","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir is a prodrug that is converted to its active form (oseltamivir carboxylate) in the body. The active metabolite binds to and inhibits influenza virus neuraminidase, an enzyme responsible for cleaving sialic acid receptors on host cell surfaces. By blocking this enzyme, oseltamivir prevents newly formed viral particles from being released from infected cells, thereby limiting viral replication and transmission.","oneSentence":"Oseltamivir phosphate inhibits viral neuraminidase, preventing the release of influenza virus particles from infected cells and reducing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:04.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection"},{"name":"Prophylaxis of influenza A and B in high-risk patients"}]},"trialDetails":[{"nctId":"NCT04183725","phase":"PHASE4","title":"Clinical Study of Reduning Injection for the Treatment of Influenza in Children","status":"UNKNOWN","sponsor":"China Academy of Chinese Medical Sciences","startDate":"2019-12-01","conditions":"Influenza in Children","enrollment":240},{"nctId":"NCT02989012","phase":"PHASE2","title":"Phase IIaTrials of GanMaoKangNing Granules","status":"UNKNOWN","sponsor":"Dalian Zhen-Ao Bio-Tech Co., Ltd.","startDate":"","conditions":"Epidemic Influenza","enrollment":96},{"nctId":"NCT02232945","phase":"PHASE4","title":"Banlangen Granules Anti-seasonal Influenza Study","status":"UNKNOWN","sponsor":"Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited","startDate":"2012-04","conditions":"Influenza","enrollment":177},{"nctId":"NCT02662426","phase":"PHASE3","title":"Lingdancao Granules in the Treatment of Seasonal Influenza","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2016-04","conditions":"Influenza","enrollment":318}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reduning injection simulants","tamiflu,0221503013","TAMIFLU®","Tamiflu"],"phase":"marketed","status":"active","brandName":"Oseltamivir phosphate granules","genericName":"Oseltamivir phosphate granules","companyName":"China Academy of Chinese Medical Sciences","companyId":"china-academy-of-chinese-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir phosphate inhibits viral neuraminidase, preventing the release of influenza virus particles from infected cells and reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection, Prophylaxis of influenza A and B in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}